Clinical Trials
30 trialsNCT02441803 2024-02-22
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00423514 2022-12-27
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00549848 2022-08-23
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT01119066 2022-08-05
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00416351 2022-05-17
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01471444 2021-12-16
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00983528 2020-08-12
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
University of California, San Diego
Phase 1/2 Terminated
NCT00857389 2020-04-07
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01160354 2019-08-28
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00903760 2018-11-15
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01025154 2018-10-09
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00990249 2018-08-07
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01444742 2018-07-03
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00626626 2018-04-25
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT00556452 2017-12-05
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00775593 2017-11-09
AML1107
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00945815 2017-11-06
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT01656031 2017-06-20
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00372619 2017-06-05
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 1/2 Completed
NCT00814164 2016-08-17
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00778375 2016-07-14
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00337168 2015-03-25
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00187096 2014-06-19
Natural Killer (NK) Cell Transplantation for AML
St. Jude Children's Research Hospital
Phase NA Completed
NCT00315705 2014-04-14
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Sanofi
Phase 1/2 Completed
NCT00724009 2014-03-18
Clofarabine Bone Marrow Cytoreduction
University of Chicago
Phase 2 Completed
NCT00943592 2014-02-27
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
University of Chicago
Phase 1/2 Completed
NCT00422032 2012-07-27
2 Arm Study of Clofarabine IV in MDS Patients
M.D. Anderson Cancer Center
Phase 2 Completed